According to data from IMS Health, Invokana reached 1.1 million dispensed outpatient prescriptions in the second quarter of 2015, followed by Farxiga with 411,000, and Jardiance with 136,000.
These three diabetes medicines are in a class of drugs for Type 2 diabetes that blocks the protein sodium glucose cotransporter 2 (SGLT2). In turn, this causes lower blood sugar by causing the kidneys to excrete some circulating glucose rather than returning it to circulation.
And from the ISMP QuarterWatch published January 13, 2016, with data from first and second quarters of 2015 we get this related drug safety facts about these still relatively new diabetes drugs:
Adverse drug event reports over the last 12 months increased roughly in line with patient exposure, with 5484 new cases for [Invokana (canagliflozin)], 1805 for [Farxiga (dapagliflozin)], and 455 for [Jardiance (empagliflozin)]. We observed increasing numbers of reports of metabolic acidosis–a potentially life-threatening disorder that has been the focus of two FDA Drug Safety Communications. Over the past 12 months we identified 168 possible cases for [Invokana (canagliflozin)], 80 for [Farxiga (dapagliflozin)], and 12 for [Jardiance (empagliflozin)].
In turn, this caused the January 2016 ISMP QuarterWatch publication to make this observation: “Whether the clinical benefits of these drugs outweigh the increasing evidence of their risks remains uncertain.”
We have written several times previously about Invokana, Farxiga, and Jardiance, as seen below:
- EMA Says Invokana / Farxiga /Jardiance Linked To Diabetic Ketoacidosis
- FDA Adds New Ketoacidosis Side Effect Warnings To Invokana Drug Label
- Invokana Label Gets New Warnings About Increased Bone Fracture Risks
- Despite Benefits Of Jardiance, There Are Still Safety Concerns
- Invokana Lawsuits Filed While FDA Investigates Side Effects Reports
- Farxiga / Jardiance / Invokana: Ketoacidosis and Kidney Failure
- Invokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic Ketoacidosis Events Is Associated With Increased Risk of Death
- May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana, Farxiga, And Jardiance, With Label Changes Possible
Be assured that we will be watching for additional drug safety warnings about Invokana, Farxiga, Jardiance, and these other new diabetes drugs.[Read this article in full at original source]
Strictly Confidential, No Obligation.